



10793/50

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor : **HAGAY, et al.**
Serial No. : **10/029,926**
Filing Date : **December 31, 2001**
For: : **SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE
CANCER THERAPY**
Examiner : **David J. Blanchard**
Art Unit : **1642**
Confirmation No. : **9603**
Attorney Docket No. : **10793/50**
Customer No. : **26646**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUMMARY OF INTERVIEW

SIR:

Interview Summary

Applicants wish to thank Examiner David Blanchard and his supervisor for the courtesies extended during a telephonic interview held on Wednesday, July 6, 2005.

No exhibit or demonstration was given during the interview. No prior art was discussed.

During the interview, claim 21 and the 35 U.S.C. §112, first paragraph rejection was addressed. Specifically, the addition of claim elements regarding the binding function of the claimed polypeptide was discussed. Applicants explained to the Examiner that the claimed polypeptide is capable of binding antigens other than glycolalicin and expressed interest in amending the claims to reflect this. The Examiner requested that if such claim amendments were made, the applicants should point out support for such amendments in the specification. Applicants agreed to do so. No other issues were discussed.

CONCLUSION

The Office is authorized to charge any fees or credit any refunds due to Kenyon & Kenyon's Deposit Account No: 11-0600.

Respectfully submitted,
KENYON & KENYON

Dated: August 8, 2005

By: Teresa Lavenue
Teresa A. Lavenue
Reg. No. 47,737

KENYON & KENYON
1500 K Street, NW
Suite 700
Washington, DC 20005
Direct Dial: 202-220-4258
Fax: 202-220-4201